
Moderna jumps premarket after Phase 3 trial, Target slides By Investing.com
Moderna shares jumped as much as 96% in premarket trading Wednesday after the drugmaker and Merck announced positive Phase 3 results for their personalized mRNA melanoma therapy, intismeran autogene (mRNA-4157/V940), combined with Merck's Keytruda . The INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint...








